دورية أكاديمية
أعرض في EDS

Complement inhibitor factor H expressed by breast cancer cells differentiates CD14 + human monocytes into immunosuppressive macrophages.

التفاصيل البيبلوغرافية
العنوان: Complement inhibitor factor H expressed by breast cancer cells differentiates CD14 + human monocytes into immunosuppressive macrophages.
المؤلفون: Smolag KI; Department of Translational Medicine, Lund University, Malmö, Sweden., Mueni CM; Department of Translational Medicine, Lund University, Malmö, Sweden., Leandersson K; Department of Translational Medicine, Lund University, Malmö, Sweden., Jirström K; Department of Clinical Sciences, Lund University, Lund, Sweden., Hagerling C; Department of Laboratory Medicine, Lund University, Lund, Sweden., Mörgelin M; Colzyx, Medicon Village, Lund, Sweden., Barlow PN; Edinburgh Biological NMR Unit, University of Edinburgh, Edinburgh, UK., Martin M; Department of Translational Medicine, Lund University, Malmö, Sweden., Blom AM; Department of Translational Medicine, Lund University, Malmö, Sweden.
المصدر: Oncoimmunology [Oncoimmunology] 2020 Mar 06; Vol. 9 (1), pp. 1731135. Date of Electronic Publication: 2020 Mar 06 (Print Publication: 2020).
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101570526 Publication Model: eCollection Cited Medium: Print ISSN: 2162-4011 (Print) Linking ISSN: 21624011 NLM ISO Abbreviation: Oncoimmunology
أسماء مطبوعة: Publication: 2015- : Philadelphia, PA : Taylor & Francis
Original Publication: Austin, TX : Landes Bioscience
مواضيع طبية MeSH: Breast Neoplasms* , Complement Factor H*, Complement Inactivating Agents ; Female ; Humans ; Macrophages ; Monocytes ; Neoplasm Recurrence, Local ; Tumor Microenvironment
مستخلص: Macrophages are a major immune cell type in the tumor microenvironment, where they display a tumor-supporting phenotype. Factor H (FH) is a complement inhibitor that also plays a role in several cellular functions. To date, the phenotype of monocytes stimulated with FH has been unexplored. We discovered that FH is a survival factor for CD14 + primary human monocytes, promoting their differentiation into macrophages in serum-free medium. This activity was localized to the C-terminal domains of FH and it was inhibited in plasma, indicating that the phenomenon may be most relevant in tissues. FH-induced macrophages display characteristics of immunosuppressive cells including expression of CD163 and CD206, release of the anti-inflammatory cytokine IL-10 and changes in metabolism. Furthermore, FH-induced macrophages express low levels of HLA-DR but high levels of co-inhibitory molecule programmed death-ligand 1 (PD-L1), and accordingly, a reduced capacity for T-cell activation. Finally, we show that FH is expressed by human breast cancer cells and that this correlates with the presence of immunosuppressive macrophages, breast cancer recurrence and severity of the disease. We propose that the expression of FH by tumor cells and the promotion of an immunosuppressive cancer microenvironment by this protein should be taken into account when considering the effectiveness of immunotherapies against breast cancer.
(© 2020 The Author(s). Published with license by Taylor & Francis Group, LLC.)
References: Int J Oncol. 2011 Dec;39(6):1421-8. (PMID: 21850370)
Front Immunol. 2014 Oct 07;5:479. (PMID: 25339954)
Immunobiology. 2012 Apr;217(4):455-64. (PMID: 22088229)
Cell Adh Migr. 2012 May-Jun;6(3):249-60. (PMID: 22568982)
Cancer Immunol Res. 2014 Sep;2(9):846-56. (PMID: 24872026)
J Immunol. 2009 Apr 15;182(8):4499-506. (PMID: 19342621)
PLoS One. 2013 May 16;8(5):e63165. (PMID: 23696797)
J Immunol. 2003 Aug 15;171(4):1652-5. (PMID: 12902462)
Nat Immunol. 2010 Oct;11(10):889-96. (PMID: 20856220)
Mol Microbiol. 2008 Nov;70(3):583-94. (PMID: 18627465)
PLoS One. 2011 Mar 21;6(3):e17911. (PMID: 21445301)
Int J Obes (Lond). 2007 Sep;31(9):1420-8. (PMID: 17593905)
Genome Biol. 2002 Jun 18;3(7):RESEARCH0034. (PMID: 12184808)
Annu Rev Immunol. 1997;15:323-50. (PMID: 9143691)
Breast Cancer Res. 2008;10(5):R79. (PMID: 18808688)
Nat Rev Immunol. 2005 Aug;5(8):641-54. (PMID: 16056256)
Eur J Immunol. 2002 Jul;32(7):1888-96. (PMID: 12115608)
Immunity. 2013 Jan 24;38(1):79-91. (PMID: 23273845)
Clin Exp Immunol. 2006 May;144(2):342-52. (PMID: 16634809)
Cancer Res. 2004 Sep 1;64(17):6310-8. (PMID: 15342420)
Immunology. 1993 Sep;80(1):140-5. (PMID: 8244456)
J Immunol. 2011 Nov 15;187(10):5408-18. (PMID: 22013115)
F1000Prime Rep. 2014 Mar 03;6:13. (PMID: 24669294)
J Leukoc Biol. 2008 Sep;84(3):623-30. (PMID: 18467655)
J Clin Pathol. 2008 Feb;61(2):197-203. (PMID: 18223096)
J Immunol. 2008 Aug 15;181(4):2610-9. (PMID: 18684951)
Curr Oncol Rep. 2017 Aug 10;19(10):64. (PMID: 28799073)
Nucleic Acids Res. 2003 Feb 15;31(4):e15. (PMID: 12582260)
Cell Death Dis. 2018 Feb 14;9(2):248. (PMID: 29445150)
Cell Death Differ. 2016 May;23(5):903-11. (PMID: 26768663)
Mol Immunol. 2003 Jan;39(10):547-56. (PMID: 12431388)
Int J Biol Markers. 2012 Oct 08;27(3):169-78. (PMID: 22610755)
Br J Cancer. 2002 Nov 4;87(10):1119-27. (PMID: 12402151)
J Chromatogr. 1983 Nov 11;278(1):53-61. (PMID: 6607264)
Biochem Biophys Res Commun. 2010 Jun 4;396(3):684-90. (PMID: 20438703)
Immunobiology. 2016 Sep;221(9):944-52. (PMID: 27262511)
Cancer Res. 1996 Oct 15;56(20):4625-9. (PMID: 8840975)
J Immunol. 2006 Sep 15;177(6):3520-4. (PMID: 16951310)
J Immunol. 2015 Feb 15;194(4):1534-44. (PMID: 25560409)
J Leukoc Biol. 2006 Oct;80(4):838-49. (PMID: 16849611)
Lupus. 2016 Oct;25(12):1328-40. (PMID: 27068115)
Immunity. 2013 Sep 19;39(3):599-610. (PMID: 24012416)
Clin Exp Immunol. 1984 May;56(2):453-8. (PMID: 6234114)
BMC Bioinformatics. 2009 May 27;10:161. (PMID: 19473525)
Nat Rev Cancer. 2004 Jul;4(7):540-50. (PMID: 15229479)
PLoS One. 2012;7(8):e42507. (PMID: 22880008)
Oncogene. 2015 Apr 2;34(14):1865-71. (PMID: 24837365)
J Immunol. 2012 Oct 1;189(7):3508-20. (PMID: 22942426)
Science. 2017 Aug 18;357(6352):. (PMID: 28818916)
J Immunol. 2016 May 15;196(10):4274-90. (PMID: 27076676)
PLoS One. 2013 Sep 16;8(9):e74250. (PMID: 24066126)
Immunity. 2014 Jul 17;41(1):14-20. (PMID: 25035950)
Int J Cancer. 2008 Aug 15;123(4):780-6. (PMID: 18506688)
Mol Cell Biol. 2005 Nov;25(21):9543-53. (PMID: 16227604)
Blood Adv. 2017 Dec 04;1(26):2510-2519. (PMID: 29296902)
J Immunol. 2006 Nov 1;177(9):6308-16. (PMID: 17056561)
BMC Cancer. 2012 Jul 23;12:306. (PMID: 22824040)
Immunity. 2017 Feb 21;46(2):261-272. (PMID: 28228282)
Cancer Treat Rev. 2017 Nov;60:24-31. (PMID: 28866366)
J Transl Med. 2017 Jul 3;15(1):152. (PMID: 28673320)
J Clin Endocrinol Metab. 2009 Nov;94(11):4619-23. (PMID: 19837929)
Nat Immunol. 2007 Jun;8(6):578-83. (PMID: 17450143)
Science. 2002 Mar 8;295(5561):1898-901. (PMID: 11884756)
J Microsc. 1993 Mar;169(3):375-382. (PMID: 33930978)
فهرسة مساهمة: Keywords: Breast cancer; factor H; macrophages
المشرفين على المادة: 0 (CFH protein, human)
0 (Complement Inactivating Agents)
80295-65-4 (Complement Factor H)
تواريخ الأحداث: Date Created: 20200914 Date Completed: 20210728 Latest Revision: 20220531
رمز التحديث: 20240829
مُعرف محوري في PubMed: PMC7453999
DOI: 10.1080/2162402X.2020.1731135
PMID: 32923173
قاعدة البيانات: MEDLINE
الوصف
تدمد:2162-4011
DOI:10.1080/2162402X.2020.1731135